OrthoAccel Technologies Inc, Houston, announced $20.5 million in debt and equity financing from its lead investor S3 Ventures. OrthoAccel manufactures and sells AcceleDent Optima, a FDA-cleared Class II medical device that is designed to speed up bone remodeling during orthodontic treatment.

“We remain excited about OrthoAccel’s global market opportunity and AcceleDent Optima’s position as the market leader of the accelerated orthodontic category,” said Brian R. Smith, managing director of S3 Ventures, who added that S3 Ventures remains committed to driving OrthoAccel’s future growth.

“We are excited to see the adoption of AcceleDent Optima increasing dramatically with our existing and new providers. In particular, we are increasingly working with more aligner focused orthodontic practices,” said Todd Cooper, president and CEO of OrthoAccel. “With the introduction of many new aligners available globally, both OrthoAccel and orthodontic practices utilizing aligner therapy will benefit from patients who want the most advanced and effective treatment options.”